Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 59 Show results per page	View Search Criteria \| Help With Results

Last Modified: 6/12/2007 First Published: 5/1/2000


1.		Phase III Randomized Study of Gemcitabine With or Without R115777 in Patients With Advanced Pancreatic Cancer (Summary Last Modified 03/2001)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				Pharmaceutical / Industry				JRF-R115777-INT-11 NCT00005648


2.		Tipifarnib Versus Best Supportive Care in the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Completed				70 and over				Pharmaceutical / Industry				CR004372 NCT00093990

Last Modified: 2/12/2007 First Published: 6/1/2000


3.		Phase I/II Study of Tipifarnib in Patients With Myeloproliferative Disorders

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Completed				21 and over				NCI				SUMC-NCI-38 NCI-38, NCT00005846, 38

Last Modified: 8/11/2006 First Published: 9/24/2003


4.		Phase Ib/II Neoadjuvant Study of Tipifarnib, Docetaxel, and Capecitabine in Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIA or IIIB Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Closed				18 and over				NCI				MAYO-MC0131 NCI-5599, 5599, NCT00070252, WSU-C-2679

Last Modified: 12/10/2008 First Published: 2/20/2004


5.		Phase I/II Study of Tipifarnib and Radiotherapy in Pediatric Patients With Non-Disseminated Intrinsic Diffuse Brainstem Gliomas (Phase I Closed to Accrual as of 1/3/06)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Closed				3 to 21				NCI				PBTC-014 NCT00079339


6.		Phase I/II Evaluation of Temozolomide and ZARNESTRA (R115777) for Recurrent and Progressive Glioblastoma Multiforme

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Temporarily closed				Not specified				Other				ID02-126 NCT00050986

Last Modified: 1/9/2007 First Published: 10/25/2004


7.		Phase I/II Study of Idarubicin, Cytarabine, and Tipifarnib in Patients With Newly Diagnosed High-Risk Myelodysplastic Syndromes or Acute Myeloid Leukemia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Closed				15 to 70				NCI				MDA-2003-0563 NCI-6625, 6625, NCT00096122

Last Modified: 8/13/2008 First Published: 12/22/2004


8.		Phase I/II Study of Tipifarnib and Gemcitabine in Women With Metastatic Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Temporarily closed				18 and over				NCI				MDA-2003-0992 7004, NCI-7004, NCT00100750

Last Modified: 11/20/2007 First Published: 10/14/2005


9.		Phase I/II Study of Tipifarnib and Bortezomib in Patients With Relapsed Multiple Myeloma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Completed				18 and over				NCI				MCC-VEL-04-111 7032, NCI-7032, NCT00243035

Last Modified: 11/1/2000 First Published: 4/1/2000


10.		Phase II Study of R115777 in Patients With Relapsed Small Cell Lung Cancer (Summary Last Modified 11/2000)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 and over				NCI, Pharmaceutical / Industry				NYU-9861 JRF-R115777-USA-8B, NCI-G00-1714, NCT00005041

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute